-
Deepening its integration with digitalization, the pharmaceutical company established a digital technology company
Time of Update: 2022-11-04
It is reported that in order to improve the overall operation efficiency of the supply chain and meet the new procurement needs of the group and subsidiaries brought about by the rapid development of the company, Hengrui Pharmaceutical also signed a contract with Zhenyun Technology in 2021, and the two parties reached a consensus on the implementation plan of the procurement management platform to jointly provide more agile solutions for the digital transformation of Hengrui Pharmaceutical's supply chain.
-
Harbour Biomed announced that the Phase I clinical trial of B7H4x4-1BB bispecific antibody has completed the first patient dosing in the United States
Time of Update: 2022-11-04
Dr. Jinsong Wang, Founder, Chairman and Chief Executive Officer of Harbour Bio Pharma, said, "We are pleased to complete the first patient dosing of B7H4x4-1BB in the United States, which is another milestone in Harbour Bio Pharma's global leadership in next-generation immuno-oncology therapy innovation.
-
The company has changed its management to appoint a deputy general manager, and the company has changed several times since its listing
Time of Update: 2022-11-01
【Pharmaceutical Network Enterprise News】On October 25, 2022, Luyan Pharmaceutical announced that upon nomination by the general manager of the company, the company agreed to appoint Mr. Wu Di as the d
-
Mengke Pharmaceutical actively announced R&D data at IDWeek 2022 to help the treatment of multidrug-resistant infections
Time of Update: 2022-10-31
Data from four completed phase II and III skin and soft tissue infection clinical trials showed that the primary efficacy and safety of subjects with mild and moderate renal impairment were comparable to those with normal renal function without the need to adjust the CZD/CZA dose.
-
In order to expand the business of traditional Chinese medicine formula granules, a pharmaceutical company has obtained more than 200 listing filing certificates
Time of Update: 2022-10-31
【Pharmaceutical Network Enterprise News】Recently, Jilin Ao Dong issued an announcement that 6 products of Yanbian Pharmaceutical, a holding subsidiary, obtained the "Chinese Medicine Formula Granules Market Filing Certificate".
-
Tianxing Pharmaceutical will announce its clinical data of ADG116, an anti-CTLA-4 new epitope antibody, in poster form at the 2022 SITC Annual Meeting
Time of Update: 2022-10-31
m. Beijing time Exhibition location (on-site participants): Poster hall Abstract number: 753 : Preliminary update on the Phase 1b/2 open-label, dose escalation and expansion study of the anti-CTLA-4 neoepitope antibody NEObody™ADG116 in combination with pembrolizumab in patients with advanced/metastatic solid tumors Display date: Thursday, November 10, 2022 (abstract release date, November 7) Exhibition time: 9:00 a.
-
Ascletis announced that it has submitted a clinical trial application for the monkeypox indication of the oral antiviral drug ASC10 in the United States
Time of Update: 2022-10-31
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") announced on October 26 that it has submitted an application for a New Drug Clinical Trial (IND) for ASC10, an oral inhibitor candidate for monkeypox virus polymerase, to the U.
-
Transcenta Group will announce the latest business progress of the TST003 project, the first antibody of its kind, at the 10th TEMTIA meeting
Time of Update: 2022-10-31
Presentation Details: : TST003, a first-of-its-kind anti-Gremlin1 monoclonal antibody, can block epithelial mesenchymal transformation, showing promising antitumor activity of a single agent against a variety of refractory solid tumors Date & Time: 9 November 2022, 3:30pm-3:45pm (Paris time) Speaker: Dr. Xueming Qian, CEO of Transcenta Group TEMTIA is an international conference dedicated to the study of epithelial mesenchymal transformation (EMT).
-
Large clinical studies have proved that the medium large intestinal microbiome formula (SIM01) can reduce the risk of new crown and other bacterial and viral infections
Time of Update: 2022-10-31
A large-scale clinical double-blind study conducted by the Faculty of Medicine of Chinese University of Hong Kong (CUHK) found that the microecological formula SIM01 developed by the Faculty of Medicine of University (CUHK) can reduce the common adverse reactions of high-risk groups such as the elderly and diabetics after vaccination.
-
CAR-T cell therapy: precise targeting, promising future
Time of Update: 2022-10-31
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar of cancer immune cell therapy, which has shown significant clinical treatment effects in patients with B-cell leukemia or lymphoma, but CAR-T therapy is helpless in the face of solid tumors, and CAR-T therapy also has serious life-threatening toxicity and limited anti-cancer efficacy.
-
Ascentage Pharma submitted an IND application for the treatment of systemic lupus erythematosus with the Bcl-2 inhibitor APG-2575, which will open up the exploration of non-oncology fields
Time of Update: 2022-10-31
Ascentage Pharma (6855. HK) announced on October 26 that it has officially submitted a new drug clinical trial (IND) application to the Center for Drug Evaluation (CDE) of the National Medical Produc
-
Shanghai Lu Xiangyi brought the "hardcore" eye-catching centrifuge to the 19th CACLP
Time of Update: 2022-10-31
Group photo of some Shanghai Lu Xiangyi (Image source: All pictures in this article are provided by Shanghai Lu Xiangyi)【Pharma Network Exhibitor News】The 19th China (International) Laboratory Medicine and Blood Transfusion Instrument Reagent Expo (CACLP) has been officially held in Nanchang, Jiangxi Province on October 26, 2022.
-
Innovation and transformation is not easy! After spending nearly $400 million to introduce ADCs, the pharmaceutical company's non-net profit fell by 17.62%
Time of Update: 2022-10-31
In the first three quarters, the fair value of financial assets held by I-Mab and CARsgen Pharmaceuticals decreased during the reporting period, which was only a short-term impact on the company's net profit attributable to the parent.
-
The Phase II clinical trial of Pioneer Pharmaceutical Freitane for the treatment of acne in China completed patient enrollment
Time of Update: 2022-10-31
Dr. Youzhi Tong, Founder, Chairman and CEO of Pioneer Pharmaceutical, said, "We are delighted to see that the Phase II clinical trial in China of Freitane for acne has completed the enrollment of all patients.
-
Another important result: Bang Yao Biologics Nature Chemical Biology publishes a paper to develop a precise and safe new adenine base editor -- "ABE9"
Time of Update: 2022-10-31
Base editing technology was first developed by David R. Liu's team at Harvard University, and is mainly divided into two categories: cytosine base editor (CBE) and adenine base editor (ABE), which ar
-
deCODE Genetics publishes research reports
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Scientists at deCODE genetics, a subsidiary of Amgen, published a large genome-wide association study on nonalcoholic fatty liver disease (NASLD) in Nature Genetics on October 24.
-
Medical devices are prosperous, and the company expects net profit to increase by more than 30,000% in the first three quarters of this year
Time of Update: 2022-10-31
On the evening of October 14, Jiuan Medical disclosed its performance forecast for the first three quarters, expecting the net profit attributable to shareholders of listed companies in the first three quarters to be 16 billion yuan to 16.
-
Innovent Biologics announces the publication of the high-dose cohort results of Mazdutide's Phase Ib clinical study in overweight or obese subjects in China, in the Lancet eClinicalMedicine
Time of Update: 2022-10-31
, announced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor, GCGR) dual agonist mazdutide (IBI362) results from a high-dose cohort of a multi-dose phase Ib clinical study in overweight or obese subjects in China were published online in the internationally renowned medical journal eClinicalMedicine (IF: 17.
-
Keyue Pharmaceutical announced that the application for a Phase II clinical trial of KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been approved by the National Medical Products Administration of China
Time of Update: 2022-10-31
Keyue Pharmaceutical, a global biotechnology company dedicated to the development of a new generation of complement drugs for the treatment of immune-mediated diseases, today announced that the China National Medical Products Administration (NMPA) has approved its Application for New Drug Application (CTA) for its Phase II clinical trial of KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
-
Yiling Pharmaceutical's R&D expenditure reached 552 million yuan in the first three quarters, and the transformation of traditional Chinese medicine achievements accelerated
Time of Update: 2022-10-31
Under the guidance of network disease theory, Yiling Pharmaceutical has developed 13 innovative patented traditional Chinese medicines, covering diseases with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and so on.
